Lead Product(s) : Docarpamine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Martin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Martin Pharmaceuticals Licenses Docarpamine for Liver Disease from Mitsubishi
Details : Martin gains exclusive access to Ciquaax (docarpamine) related toxicology, preclinical, clinical safety, and pharmacokinetics data in the field of gastrointestinal conditions, including ascites.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Docarpamine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Martin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement